Pages that link to "Q47807462"
Jump to navigation
Jump to search
The following pages link to Lack of BRAF mutation in primary uveal melanoma. (Q47807462):
Displaying 50 items.
- Brn-2 expression controls melanoma proliferation and is directly regulated by beta-catenin (Q24317170) (← links)
- The Brn-2 transcription factor links activated BRAF to melanoma proliferation (Q24599712) (← links)
- Analysis of the genome to personalize therapy for melanoma (Q24601008) (← links)
- Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases (Q24814098) (← links)
- Melanoma: from mutations to medicine (Q27024061) (← links)
- Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF (Q28251989) (← links)
- Melanoma genetics and the development of rational therapeutics (Q33726956) (← links)
- Ocular melanoma: an overview of the current status (Q34653896) (← links)
- BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs (Q35588657) (← links)
- Genetic and molecular characterization of uveal melanoma cell lines (Q35783799) (← links)
- Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma (Q35812275) (← links)
- Biomarkers in melanoma: stage III and IV disease. (Q36050541) (← links)
- Frequency of BRAF Mutation and Clinical Relevance for Primary Melanomas (Q36343518) (← links)
- Molecular pathology of uveal melanoma (Q36615059) (← links)
- Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. (Q36615986) (← links)
- Role of MC1R variants in uveal melanoma (Q36671646) (← links)
- A Rare Thyroid Metastasis from Uveal Melanoma and Response to Immunotherapy Agents (Q36773500) (← links)
- BRAF, GNAQ, and GNA11 mutations and copy number in pediatric low-grade glioma (Q36811872) (← links)
- The T1799A point mutation is present in posterior uveal melanoma (Q36977553) (← links)
- Understanding signaling cascades in melanoma (Q37034487) (← links)
- BRAF kinase in melanoma development and progression. (Q37086193) (← links)
- Malignant melanoma in the 21st century: the emerging molecular landscape (Q37211362) (← links)
- GNA11 Mutation in a Patient With Cutaneous Origin Melanoma: A Case Report (Q37624039) (← links)
- Genetics of uveal melanoma and cutaneous melanoma: two of a kind? (Q37772777) (← links)
- Molecular testing in malignant melanoma (Q38012416) (← links)
- Latest developments in the biology and management of uveal melanoma (Q38152310) (← links)
- The role of genetics in the pathogenesis of periocular cutaneous neoplasms: implications for targeted therapy. (Q38153719) (← links)
- The V599E BRAF mutation is uncommon in biliary tract cancers (Q38447459) (← links)
- Mutation analysis and gene expression profiling of ocular melanomas in cats. (Q38772017) (← links)
- Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies (Q38783820) (← links)
- Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives (Q38798084) (← links)
- Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma (Q38802286) (← links)
- Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target (Q38978135) (← links)
- Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner (Q39325158) (← links)
- Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile (Q39756781) (← links)
- Episodic Src activation in uveal melanoma revealed by kinase activity profiling. (Q39830805) (← links)
- Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature (Q40270911) (← links)
- Anatomic site-specific patterns of gene copy number gains in skin, mucosal, and uveal melanomas detected by fluorescence in situ hybridization (Q40344910) (← links)
- Molecular alterations in malignant blue nevi and related blue lesions (Q40505247) (← links)
- B-RAF is a therapeutic target in melanoma (Q40543086) (← links)
- Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis (Q40555586) (← links)
- Genetic profile of GNAQ-mutated blue melanocytic neoplasms reveals mutations in genes linked to genomic instability and the PI3K pathway. (Q41354063) (← links)
- Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea (Q43998617) (← links)
- Outcomes of patients with metastatic melanoma treated with molecularly targeted agents in phase I clinical trials (Q44932310) (← links)
- Absence of V599E BRAF mutations in desmoplastic melanomas. (Q45217488) (← links)
- Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction (Q46422651) (← links)
- Frequent and Yet Unreported GNAQ and GNA11 Mutations are Found in Uveal Melanomas. (Q47223959) (← links)
- Analysis of the oncogene BRAF mutation and the correlation of the expression of wild-type BRAF and CREB1 in endometriosis (Q47246686) (← links)
- Image-Guided Transarterial Chemoembolization With Drug-Eluting Beads Loaded with Doxorubicin (DEBDOX) for Unresectable Hepatic Metastases from Melanoma: Technique and Outcomes (Q47321056) (← links)
- Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma (Q47966722) (← links)